CLAIM LISTING:

1. (Original) A compound of the formula:



I

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is hydrogen or alkyl;

R^2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or $-Y^1$-C(O)-Y^2 -R^{11} (where Y^1 and Y^2 are independently either absent or an alkylene group and R^{11} is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

R^3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterosubstituted cycloalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, –alkylene–C(=O)–R^4 (where R^4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), or acyl;

Ar^1 is aryl;

X^1 is O, NR^5 or S, where R^5 is hydrogen or alkyl; and

X^2 is a bond, O, NR^6, S or CH_2, where R^6 is hydrogen or alkyl.

2. (Original) The compound according to Claim 1 of the formula:



3. (Original) The compound according to Claim 2, wherein X^1 is O.

4. (Original) The compound according to Claim 3, wherein R^1 is hydrogen.

5. (Original) The compound according to Claim 4, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

6. (Original) The compound according to Claim 5, wherein R^3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

7. (Original) The compound according to Claim 4, wherein R^2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

8. (Original) The compound according to Claim 7, wherein R^2 is optionally substituted phenyl.

9. (Currently amended) The compound according to Claim ~~8,wherein~~ 8, wherein R^2 is heterocyclylphenyl, alkylthiophenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, phenyl, halophenyl, hydroxyphenyl, acylphenyl, cyanophenyl, alkoxycarbonylphenyl, carboxamidophenyl, N-alkylcarboxamidophenyl, N,N-dialkylcarboxamidophenyl, alkylsulfonyloxyphenyl, carbamoylphenyl, N-alkylcarbamoylphenyl or N,N-dialkylcarbamoylphenyl

10. (Original) The compound according to Claim 9, wherein R^3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

11. (Original) The compound according to Claim 7, wherein Ar^1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

12. (Original) The compound according to Claim 2, wherein R^1 is hydrogen.

13. (Original) The compound according to Claim 12, wherein R^2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

14. (Original) The compound according to Claim 13, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

15. (Original) The compound according to Claim 14, wherein Ar^1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

16. (Original) The compound according to Claim 1, wherein X^2 is a bond or CH_2.

17. (Original) The compound according to Claim 16, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

18. (Original) The compound according to Claim 17, wherein R^1 is hydrogen.

19. (Original) The compound according to Claim 18, wherein R^2 is heteroalkyl, heterocyclyl, or heterosubstituted cycloalkyl.

20. (Original) The compound according to Claim 19, wherein X^1 is O.

21. (Original) A composition comprising:

(a) a compound of Claim 1; and

(b) a pharmaceutically acceptable excipient.

22. (Original) A method for treating a p38 MAP kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1.

23. (Original) The method of Claim 22, wherein the p38 mediated disorder is arthritis, Crohn's disease, inflammatory bowel disease, adult respiratory distress syndrome, or chronic obstructive pulmonary disease.

24. (Original) The method of Claim 22, wherein the p38 mediated disorder is Alzheimer's disease.

25. (Currently amended) A method for treating an FGFR kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1, wherein said FGFR kinase mediated disorder comprises atherosclerosis.

26. (canceled).

27. (Original) A method for producing a compound of the formula:



I

said method comprising the steps of contacting a compound of the formula:



with an amine compound of the formula R^1R^2NH to produce a compound of Formula.

wherein

R^1 is hydrogen or alkyl;

R^2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl or $-Y^1$-C(O)-Y^2 -R^{11} (where Y^1 and Y^2 are independently either absent or an alkylene group and R^{11} is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

R^3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, –alkylene–C(=O)–R^4 (where R^4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl;

Ar^1 is aryl;

X^1 is O, NR^5 or S, where R^5 is hydrogen or alkyl;

X^2 is a bond, O, NR^6, S or CH_2, where R^6 is hydrogen or alkyl;

n is an integer from 0 to 2; and

R^7 is an alkyl group.

28. (Original) The method of Claim 27 wherein:

R^1 is hydrogen;

R^2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl;

R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl;

Ar^1 is aryl;

X^1 is O;

X^2 is a bond; and

n is 1 or 2.

29. (Canceled)

30. (Original) The compound of claim 10, wherein R^3 is methyl.

31. (Original) The compound of claim 30, wherein R^2 is 4-(morpholin-4-yl)phenyl.

32. (Original) The compound of claim 31, wherein Ar^1 is 2-bromophenyl.

33. (Original) The compound of claim 31, wherein Ar^1 is 2,6-dichlorophenyl.

34. (Original) The compound of claim 30, wherein R^2 is 3-methylsulfinylphenyl.

35. (Original) The compound of claim 34, wherein Ar^1 is 2-bromophenyl.

* * * * *